The increase in sclerostin and FGF23 levels, two molecules secreted by osteocytes, and the consequent repression of Wnt-β catenin signaling pathway represent a clear mechanistic example explaining the impairment of bone health from the onset of CKD (Figure 1) (Cejka et al., 2012; Moysés and Schiavi, 2015; Drüeke and Massy, 2016). This evidence concerns the gene FGF23 and chronic kidney disease.